Helen Albert

Berlin, Germany

Freelance Science Journalist at Freelance

Senior Editor at Inside Precision Medicine

Freelance journalist. Focus: med, life sci, bioanth & biotech. Bylines: Forbes, BMJ, New Scientist, Chemistry World, Labiotech & more. Senior ed. @Inside_PM

Featured in: Favicon

insideprecisionmedicine.com Favicon

bioworld.com Favicon

forbes.com Favicon

newscientist.com Favicon

forbes.com.br Favicon

forbesjapan.com Favicon

genengnews.com Favicon

chemistryworld.com Favicon

labiotech.eu Favicon

sciencebusiness.net + 8 more

Articles

Incyte Partners with Qiagen to Create Diagnostic for Rare Blood Cancers

1 week ago | insideprecisionmedicine.com | Helen Albert

Rare blood cancer specialist Incyte has announced it will partner with diagnostic test expert Qiagen to create a sequencing panel to accompany several investigative therapies being developed by Incyte to treat rare blood cancers.
Europe and US face diminishing lithium supply for electric vehicle batteries

1 week ago | chemistryworld.com | Helen Albert

Lithium supplies in Europe and the US will not meet demand for electric vehicle batteries by 2030, despite significant predicted increases in production over this time, new research suggests. Source: © Xeni4ka/Getty Images China is predicted to continue its control of the market with greater access to imported lithium and better refining capacity than other regions, as well as a large domestic electric battery industry.
Extracellular Vesicle Diagnostic Platform Launched by Mursla Bio

1 week ago | insideprecisionmedicine.com | Helen Albert

U.K. biotech Mursla Bio has launched an artificial intelligence (AI)-based platform that can diagnose and monitor cancers based on data from extracellular vesicles—small, membrane-bound particles released by almost all types of cells—in the blood. The company was launched in 2019 and specializes in detection and analysis of extracellular vesicle data from different organs.
Founder’s Nonprofit TTAM to Acquire 23andMe in Surprise Turnaround

1 week ago | insideprecisionmedicine.com | Helen Albert

Anne Wojcicki, co-founder and former CEO of direct-to-consumer genetic testing company 23andMe, has succeeded in a bid to buy almost all the assets of the bankrupt company through a nonprofit set up by Wojcicki in May this year called TTAM.
Harnessing AI Innovation to Modernize Clinical Trials

2 weeks ago | insideprecisionmedicine.com | Helen Albert |Kathy Vuksanaj

Clinical trials are an essential part of bringing new medicines to patients but are often slow and expensive to complete. Innovations in artificial intelligence (AI) over the last two decades are already having a positive impact on the way these trials are run and have the potential to improve them further in many ways, ranging from simple economics to more diverse trial cohorts.
Schizophrenia Drug Delivery Technology Shows Promise

2 weeks ago | insideprecisionmedicine.com | Helen Albert

A special type of slow-release drug delivery technology, developed by Lyndra Therapeutics, allows schizophrenia or schizoaffective disorder patients to take one pill of risperidone once a week rather than daily. The pill, which expands into a larger star shape after being swallowed and slowly dissolves in the stomach over a week, performed well in an open label, non-randomized Phase III trial in patients with schizophrenia.
Digital Twins Help People with Type 1 Diabetes Control Their Condition

2 weeks ago | insideprecisionmedicine.com | Helen Albert

A digital twin can help people with type 1 diabetes to better control their condition using artificial pancreas technology, shows research led by the University of Virginia. Automated insulin delivery (AID) systems combined with continuous glucose sensors, known as an artificial pancreas, are becoming more commonly used by people with type 1 diabetes. The artificial pancreas technology has the potential to significantly improve blood glucose control in people with this condition.
Aneira is Bringing Precision Medicine to Women’s Health | Inside Precision Medicine

2 weeks ago | insideprecisionmedicine.com | Helen Albert

Aneira Health is progressing precision medicine in women's health by working with female staff at Guy’s and St Thomas’ Hospital in London.
In Conversation with Chris Loose, CEO and Co-founder of Progentos Therapeutics

2 weeks ago | insideprecisionmedicine.com | Helen Albert |Kathy Vuksanaj

Current therapies targeting multiple sclerosis (MS) primarily target the symptoms of the disease but do not repair neurological damage caused by the condition. This is something that Chris Loose, PhD, CEO and co-founder of Progentos Therapeutics, and his colleagues are hoping to remedy. MS is a chronic, immune-mediated condition that results in the demyelination of neurons in the central nervous system.
Stronger and longer bioluminescence for viral detection

3 weeks ago | cen.acs.org | Helen Albert

Since the COVID-19 pandemic, many point-of-care diagnostic tests have reached the market, but despite this, many have only limited accuracy. "One major problem with almost all of these rapid tests is the sensitivity and specificity of these assays, especially when you're dealing with samples with a clinically relevant, low amount of the target virus," explains Hadi Shafiee, whose team develops new diagnostic tools at Harvard Medical School.